Rehmann Capital Advisory Group Sells 1,419 Shares of AstraZeneca PLC $AZN

Rehmann Capital Advisory Group reduced its position in AstraZeneca PLC (NASDAQ:AZN) by 12.6% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 9,871 shares of the company’s stock after selling 1,419 shares during the period. Rehmann Capital Advisory Group’s holdings in AstraZeneca were worth $690,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the company. Larson Financial Group LLC lifted its position in AstraZeneca by 297.9% during the 1st quarter. Larson Financial Group LLC now owns 386 shares of the company’s stock valued at $28,000 after purchasing an additional 289 shares during the period. Richardson Financial Services Inc. raised its stake in shares of AstraZeneca by 59.8% during the second quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock worth $28,000 after buying an additional 149 shares during the last quarter. Costello Asset Management INC acquired a new position in AstraZeneca in the first quarter valued at approximately $29,000. Maseco LLP acquired a new position in shares of AstraZeneca in the 2nd quarter valued at $34,000. Finally, Caitong International Asset Management Co. Ltd bought a new position in AstraZeneca during the 1st quarter worth approximately $37,000. Institutional investors own 20.35% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on AZN. Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “hold” rating to a “sell” rating in a research note on Thursday, October 16th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, October 8th. Finally, Berenberg Bank set a $97.00 price objective on shares of AstraZeneca in a research note on Wednesday, July 9th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and an average price target of $86.00.

AstraZeneca Stock Performance

NASDAQ AZN opened at $83.40 on Friday. The company has a market cap of $258.66 billion, a P/E ratio of 31.35, a PEG ratio of 1.54 and a beta of 0.36. The company has a fifty day simple moving average of $80.79 and a 200 day simple moving average of $74.22. AstraZeneca PLC has a 12-month low of $61.24 and a 12-month high of $86.57. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.55.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.09. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The firm had revenue of $14.46 billion during the quarter, compared to the consensus estimate of $14.08 billion. During the same quarter in the prior year, the company earned $1.24 EPS. The business’s revenue for the quarter was up 16.1% on a year-over-year basis. Sell-side analysts predict that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

AstraZeneca Cuts Dividend

The company also recently declared a semi-annual dividend, which was paid on Monday, September 8th. Stockholders of record on Friday, August 8th were issued a $0.505 dividend. The ex-dividend date of this dividend was Friday, August 8th. This represents a dividend yield of 200.0%. AstraZeneca’s dividend payout ratio is presently 37.97%.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.